

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
/qjl/	A55	2003/0082140	05/01/03	Fisher	424	93.2	08/20/01
↓	A56	2004/0191223	09/30/04	Fisher	424	93.2	02/20/04
↓	A57	2005/0191277	09/01/05	Fisher	424	93.2	01/31/05
↓	A58	2005/0250127	11/10/05	Fisher <i>et al.</i>	435	6	12/22/04
↓	A59	2006/0110376	05/25/06	Fisher <i>et al.</i>	424	93.21	06/22/05

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/qjl/	C271	Ramesh <i>et al.</i> , "MDA-7/IL-24 is a Novel Ligand that Regulates Angiogenesis via the IL-22 Receptor," <i>Cancer Gene Therapy</i> , 10:S03, 2002 (Abstract No. 008).

25780713.1

EXAMINER: /Q. Janice Li/ (06/07/2007)	DATE CONSIDERED:
---------------------------------------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)	Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicant: Sunil Chada <i>et al.</i>	
	Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/qjl/	C262	Bocangel <i>et al.</i> , "Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells," <i>Cancer Gene Therapy</i> , 1-11, 2006.
	C263	Chada <i>et al.</i> , "mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biological therapies and radiotherapy: correlation with expression of bcl-2 family members," <i>Cancer Gene Therapy</i> , 1-13, 2005.
	C264	Emdad <i>et al.</i> , "Ionizing Radiation Enhances Adenoviral Vector Expressing mda-7/IL-24-mediated Apoptosis in Human Ovarian Cancer," <i>J. Cell Physiol.</i> , 208:298-306, 2006.
	C265	Inoue <i>et al.</i> , "MDA-7/IL-24-Based Cancer Gene Therapy: Translation from the Laboratory to the Clinic," <i>Current Gene Therapy</i> , 6:73-91, 2006.
	C266	Kawabe <i>et al.</i> , "Adenovirus-Mediated mda-7 Gene Expression Radiosensitizes Non-Small Cell Lung Cancer Cells via TP53-Independent Mechanisms," <i>Molecular Therapy</i> , 6:637-644, 2002.
	C267	McKenzie <i>et al.</i> , "Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells," <i>Surgery</i> , 136:437-442, 2004.
	C268	Nishikawa <i>et al.</i> , "Adenoviral-mediated mda-7 expression suppresses DNA repair capacity and radiosensitizes non-small-cell lung cancer cells," <i>Oncogene</i> , 23:7125-7131, 2004.
	C269	Nishikawa <i>et al.</i> , "Adenovirus-Mediated mda-7 (IL24) Gene Therapy Suppresses Angiogenesis and Sensitizes NSCLC Xenograft Tumors to Radiation," <i>Mol. Therapy</i> , 9:818-828, 2004.

25751368.1

EXAMINER: /Q. Janice Li/ (06/07/2007)      DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)	Atty. Docket No.:	Serial No.:
List of Patents and Publications for Applicant's	INGN:097US	10/017,472
INFORMATION DISCLOSURE STATEMENT	Applicant:	
	Sunil Chada <i>et al.</i>	
(Use several sheets if necessary)	Filing Date:	Group:
	December 7, 2001	1633
U.S. Patent Documents	Foreign Patent Documents	Other Art
<i>See Page 1</i>	<i>See Page 1</i>	<i>See Page 1-2</i>

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/qjl/	C270	Su <i>et al.</i> , "Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2," <i>Oncogene</i> , 25:2339-2348, 2006.

25751368.1

<b>EXAMINER:</b>	/Q. Janice Li/ (06/07/2007)	<b>DATE CONSIDERED:</b>
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.		

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A40	09/615,154	07/13/00	Mhashikar <i>et al.</i>			07/13/00
/qjl/	A41	2002/0183271	12/05/02	Chada <i>et al.</i>	514	44	12/07/01
	A42	2002/0001048	07/11/02	<del>Chada <i>et al.</i></del>	514	44	11/21/01
/qjl/	A43	2003/0147966	08/07/03	Franzen <i>et al.</i>	424	491	07/10/02
	A44	2003/0223938	12/04/03	Nagy <i>et al.</i>	424	46	04/14/03
	A45	2004/0009939	01/15/04	Chada <i>et al.</i>	514	44	03/03/03
	A46	2005/0101770	05/12/05	Presta	530	388.15	11/09/04
	A47	2005/0143336	06/30/05	Ramesh <i>et al.</i>	514	44	11/30/04
	A48	2006/0134801	06/22/06	Chada <i>et al.</i>	436	177	03/02/04
	A49	5,179,122	01/12/93	Greene <i>et al.</i>	514	458	02/11/91
	A50	5,747,469	05/05/98	Roth <i>et al.</i>	514	44	04/25/94
	A51	6,132,980	10/17/00	Wang <i>et al.</i>	435	7.23	09/28/98
	A52	6,168,791	01/02/01	Larsen <i>et al.</i>	424	158.1	05/21/98
	A53	6,407,218	06/18/02	Tamarkin <i>et al.</i>	530	389.1	11/10/98
	A54	60/661,680	03/14/05	Lin			03/14/05

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
/qjl/	B11	WO 00/61626	10/19/00	WIPO	English
	B12	WO 01/60365	08/23/01	WIPO	English
	B13	WO 02/04511	01/17/02	WIPO	English
	B14	WO 02/45737	06/13/02	WIPO	English
	B15	WO 03/075952	09/18/03	WIPO	English

25746887.1

EXAMINER: /Q. Janice Li/ (06/07/2007)

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
/qjl/	B16	WO 03/087308	10/23/03	WIPO	English
/qjl/	B17	WO 98/16655	04/23/98	WIPO	English
/qjl/	B18	WO 98/35554	08/20/98	WIPO	English

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/qjl/	C130	Albert <i>et al.</i> , "Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells," <i>Nat Immunol</i> , 2(11):1010-1017, 1998.
	C131	Alberts <i>et al.</i> "Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase," <i>J. Cell. Biochem. Supp.</i> , 22:18-23, 1995.
	C132	Alshafie <i>et al.</i> , "Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model," <i>Oncology Reports</i> , 7:1377-1381, 2000.
	C133	Barber, GN., "Host defense, viruses and apoptosis," <i>Cell Death Differ.</i> , 8(2):113-126, 2001.
	C134	Basu <i>et al.</i> , "Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer," <i>Mol. Cancer Res.</i> , 2:632-642, 2004.
	C135	Bedi <i>et al.</i> , "Inhibition of apoptosis during development of colorectal cancer," <i>Cancer Res.</i> , 55(9):1811-1816, 1995.
	C136	Benoit <i>et al.</i> , "Cardiac-specific transgenic overexpression of alpha1B-adrenergic receptors induce chronic activation of ERK MAPK signalling," <i>Biochem. Cell Biol.</i> , 82(6):719-727, 2004.
	C137	Benoit <i>et al.</i> , "Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2," <i>Oncogene</i> , 23:1631-1635, 2004.
	C138	Beretta <i>et al.</i> , "Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation," <i>EMBO J</i> , 15:658-664, 1996.
✓	C139	Beretta <i>et al.</i> , "Rapamycin stimulates viral protein synthesis and augments the shutoff of host protein synthesis upon picornavirus infection," <i>J. Virol</i> , 70:8993-8996, 1996.

25746887.1

EXAMINER: /Q. Janice Li/ (06/07/2007)

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1-2	Other Art See Page 2-12	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/qjl/	C140	Bonvini <i>et al.</i> , "Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription," <i>Cancer Res.</i> , 61:1671-1677, 2001.
	C141	<del>Bowie <i>et al.</i>, "Deciphering the message in protein sequences: tolerance to amino acid substitutions," <i>Science</i>, 247(4948):1306-10, 1990</del>
	C142	Chada <i>et al.</i> , "Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism," <i>Mol. Ther.</i> , 10(6):1085-1095, 2004.
	C143	Chada <i>et al.</i> , "MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family," <i>Int. Immunopharmacol.</i> , 4:649-667, 2004.
	C144	Chada <i>et al.</i> , "The multifunctional mda-7 gene encodes both tumor suppressor and TH1 cytokine (IL-24) activities," <i>Cancer Gene Therapy</i> , 10:S3, 2003
	C145	Chattergoon <i>et al.</i> , "Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis," <i>Nat Biotechnol.</i> , 18(9):974-979, 2000.
	C146	Craven <i>et al.</i> , "A decade of tyrosine kinases: from gene discovery to therapeutics," <i>Surg. Oncol.</i> , 12(1):39-49, 2003.
	C147	Cross <i>et al.</i> , "A p53-dependent mouse spindle checkpoint," <i>Science</i> , 267:1353-1356, 1995.
	C148	Cunningham <i>et al.</i> , "Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study," <i>Molecular Therapy</i> , 11(1):149-159, 2005. (Written in 2003 with Applicant)
	C149	Daigo <i>et al.</i> , "Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3," <i>Cancer Research</i> , 59:1966-1972, 1999.
	C150	<del>Database accession No. U70824, GenBank.</del>
	C151	<del>Database accession No. U70880, GenBank.</del>
/qjl/	C152	Database UniProt, "Interleukin-24 precursor (suppression of tumorigenicity 16 protein) (melanoma differentiation-associated gene 7 protein) (MDA-7)," UniProt accession no.: Q13007, 2004.
/qjl/	C153	Denkert <i>et al.</i> , "Prognostic impact of cyclooxygenase-2 in breast cancer," <i>Clin. Breast Cancer</i> , 4(6):428-433, 2004.

25746887.1

EXAMINER: /Q. Janice Li/ (06/07/2007)

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/qjl/	C154	Donze <i>et al.</i> , "The Hsp90 chaperone complex is both a facilitator and a repressor of the dsRNA-dependent kinase PKR," <i>EMBO J.</i> , 20:3771-3780, 2001.
	C155	Dumoutier and Renauld, "Viral and cellular interleukin-10 (IL-10)-related cytokines: from structures to functions," <i>Eur Cytokine Netw</i> , 13(2):5-15, 2002.
	C156	Earnest <i>et al.</i> , "Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention," <i>J. Cell Biochem. Suppl.</i> , 161:156-166, 1992.
	C157	El-Rayes <i>et al.</i> , "Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines," <i>Mol. Cancer Ther.</i> , 3:1421-1426, 2004.
	C158	Fariss <i>et al.</i> , "The selective antiproliferative effects of alpha-tocopheryl hemisuccinate and cholesteryl hemisuccinate on murine leukemia cells result from the action of the intact compounds," <i>Cancer Res.</i> , 54:3346-3351, 1994.
	C159	Feng <i>et al.</i> , "Identification of double-stranded RNA-binding domains in the interferon-induced double-stranded RNA-activated p68 kinase," <i>Proc. Natl. Acad. Sci., USA</i> , 89:5447-5451, 1992.
	C160	Fisher <i>et al.</i> , "mda-7/LI-24, a novel cancer selective apoptosis inducing cytokine gene," <i>Cancer Biol Therapy</i> , 2(4 suppl. 1):S24-S37, 2003.
	C161	Fraley <i>et al.</i> , "Entrapment of a bacterial plasmid in phospholipid vesicles: potential for gene transfer," <i>Proc. Natl. Acad. Sci. USA</i> , 76:3348-3352, 1979.
	C162	Gale <i>et al.</i> , "Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase," <i>J. Virol</i> , 7(8):6505-6516, 1999.
	C163	Gale <i>et al.</i> , "Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation," <i>Mol. Cell Biol.</i> , 18:5208-5218, 1998.
	C164	Gale <i>et al.</i> , "Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance," <i>Clinical and Diagnostic Virology</i> , 10:157-162, 1998.
	C165	Gale <i>et al.</i> , "Translational control of viral gene expression in Eukaryotes," <i>Microbiol Mol Biol Rev</i> , 64(2):239-280, 2000.
	C166	Gann <i>et al.</i> , "Low-dose aspirin and incidence of colorectal tumors in a randomized trial," <i>J. Natl. Cancer Inst.</i> , 85:1220-1224, 1993.

25746887.1

EXAMINER: /Q. Janice Li/ (06/07/2007)

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/qjl/	C167	Garn <i>et al.</i> , "IL-24 is expressed by rat and human macrophages," <i>Immunobiol.</i> , 205:321-334, 2002.
	C168	Garner <i>et al.</i> , "Celecoxib for rheumatoid arthritis," <i>Cochrane Database Syst Rev.</i> , (4):CD003831, 2002. (abstract only)
	C169	Gething and Sambrook, "Protein folding in the cell," <i>Nature</i> , 355(6355):33-45, 1992.
	C170	Giovannucci <i>et al.</i> , "Aspirin use and the risk for colorectal cancer and adenoma in male health professionals," <i>Ann. Intern. Med.</i> , 121:241-246, 1994.
	C171	Giovannucci <i>et al.</i> , "Physical activity, obesity, and risk of colorectal adenoma in women (United States)," <i>Cancer Causes Control</i> , 7(2):253-63, 1996. (abstract only)
	C172	Greenberg <i>et al.</i> , "Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group," <i>J. Natl. Cancer Inst.</i> , 85:912-916, 1993.
	C173	Hanif <i>et al.</i> , "Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pat," <i>Biochemical Pharmacology</i> , (52):237-245, 1996.
	C174	Harris <i>et al.</i> , "Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor," <i>Caplus</i> , Abstract Number: 2000:282718, 2000.
	C175	Howe <i>et al.</i> , "Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer," <i>Cancer Res.</i> , 62:5405-5407, 2002.
	C176	Howe <i>et al.</i> , "Cyclooxygenase-2: a target for the prevention and treatment of breast cancer," <i>Endocr. Relat. Cancer</i> , 8:97-114, 2001.
	C177	Ji <i>et al.</i> , "Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo," <i>Cancer Research</i> , 62:2715-2720, 2002
	C178	Judware <i>et al.</i> , "Partial characterization of a cellular factor that regulates the double-stranded RNA-dependent eIF-2 $\alpha$ kinase in 3T3-F442A fibroblasts," <i>Mol. Cell Biol.</i> , 11(6):3259-3267, 1991.
✓	C179	Kamal <i>et al.</i> , "A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors," <i>Nature</i> , 425:407-410, 2003.

25746887.1

EXAMINER: /Q. Janice Li/ (06/07/2007)

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1-2	Other Art See Page 2-12	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/qjl/	C180	Kaufman, "Orchestrating the unfolded protein response in health and disease," <i>J. Clin Invest</i> , 110(10):1389-1398, 2002.
	C181	Killary <i>et al.</i> , "Definition of a tumor suppressor locus within human chromosome 3p21-p22," <i>Proc Nat Acad Sci USA</i> , 89:10877-10881, 1992.
	C182	Kismet <i>et al.</i> , "Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention," <i>Cancer Detect Prev.</i> , 28(2):127-42, 2004.
	C183	Kline <i>et al.</i> , "Vitamin E: mechanisms of action as tumor cell growth inhibitors," In: <i>Proceeding of the International Conference on Nutrition and Cancer</i> , Prasad and Cole (Eds.), Amsterdam: IOS Press, 37-53, 1998.
	C184	Kline <i>et al.</i> , "Vitamin E: mechanisms of action as tumor cell growth inhibitors," <i>J. Nutr.</i> , 131: 161S-163S, 2001.
	C185	Koehne and Dubois, "COX-2 inhibition and colorectal cancer," <i>Semin. Oncol.</i> , 31(2 Suppl 7):12-21, 2004.
	C186	Kulp <i>et al.</i> , "3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells," <i>Cancer Res.</i> , 64:1444-1451, 2004.
	C187	Kumar <i>et al.</i> , "Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF- $\kappa$ B," <i>EMBO J</i> , 16:406-416, 1997.
	C188	Kumar <i>et al.</i> , "Double-stranded RNA-dependent protein kinase activates transcription fact NF- $\kappa$ B by phosphorylating I $\kappa$ B," <i>Proc. Natl. Acad. Sci., USA</i> , 91:6288-6292, 1994.
	C189	Le <i>et al.</i> , "Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling," <i>J. Biol. Chem.</i> , 280(3):2092-2104, 2005.
	C190	Lebedeva <i>et al.</i> , "Restoring apoptosis as a strategy for cancer gene therapy: focus on <i>p53</i> and <i>mda-7</i> ," <i>Semin Cancer Biol</i> , 13(2):169-178, 2003.
↓	C191	Lenardo <i>et al.</i> , "The involment of NF- $\kappa$ B in $\beta$ -interferon gene regulation reveals its role as widely inducible mediator of signal transduction," <i>Cell</i> , 57:287-294, 1989.

25746887.1

EXAMINER: /Q. Janice Li/ (06/07/2007)

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1-2	Other Art See Page 2-12	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/qjl/	C192	Leng <i>et al.</i> , "Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis," <i>Hepatology</i> , 38:756-768, 2003.
	C193	Lerman <i>et al.</i> , "The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium," <i>Cancer Research</i> , 60:6116-6133, 2000.
	C194	Liu <i>et al.</i> , "Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth," <i>Am. J. Clin. Oncol.</i> , 26:S103-109, 2003.
	C195	Lupulescu, "Control of precancer cell transformation into cancer cells: its relevance to cancer prevention," <i>Cancer Detect. Prev.</i> , 20(6):634-637, 1996.
	C196	Malafa and Neitzel, "Vitamin E succinate promotes breast cancer tumor dormancy," <i>J. Surg. Res.</i> , 93:163-170, 2000.
	C197	Malafa <i>et al.</i> , "Vitamin E inhibits melanoma growth in mice," <i>Surgery</i> , 131:85-91, 2002.
	C198	Maloney and Workman, "HSP90 as a new therapeutic target for cancer therapy: the story unfolds," <i>Expert Opin. Biol. Ther.</i> , 2:3-24, 2002. (abstract only)
	C199	Mandler <i>et al.</i> , "Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates," <i>Bioconjug. Chem.</i> , 13(4):786-791, 2002.
	C200	Maniotis <i>et al.</i> , "Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic Mimicry," <i>Am. J. Pathology</i> , 155:739-752, 1999.
	C201	Maran <i>et al.</i> , "Blockage of NF- $\kappa$ B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras," <i>Science</i> , 265:789-792, 1994.
	C202	McKenzie <i>et al.</i> , "Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells," <i>Surgery</i> , 136:437-442, 2004.
	C203	Merrick and Hershey, "The pathway and mechanism of eukaryotic protein synthesis," In: <i>Translational Control</i> , Hershey <i>et al.</i> , (Eds.), Cold Spring Harbor Laboratory Press, NY, 31-69, 1996.
✓	C204	Meurs <i>et al.</i> , "Molecular cloning and characterization of the human double-stranded RNA-activated protein kinases induced by interferon," <i>Cell</i> , 62:379-390, 1990.

25746887.1

EXAMINER: /Q. Janice Li/ (06/07/2007)

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/qjl/	C205	Meurs <i>et al.</i> , "Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase," <i>Proc. Natl. Acad. Sci., USA</i> , 90:232-236, 1993.
	C206	Mhashilkar <i>et al.</i> , "MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells." <i>Mol. Ther.</i> , 8:207-219, 2003.
	C207	Mizuguchi and Kay, "Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method," <i>Human Gene Therapy</i> , 9:2577-2583, 1998.
	C208	Narisawa <i>et al.</i> , "Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment," <i>Cancer Res.</i> , 41(5):1954-1957, 1981.
	C209	Neckers <i>et al.</i> , "Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity," <i>Invest New Drugs</i> , 17:361-373, 1999.
	C210	Nemunaitis <i>et al.</i> , "Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial," <i>Cancer Res.</i> , 60:6359-6366, 2000.
	C211	Nemunaitis, "Use of macrophage colony-stimulating factor in the treatment of fungal infections," <i>Clin Infect Dis</i> , 26(6):1279-1281, 1998.
	C212	Neuzil <i>et al.</i> , "Selective cancer cell killing by $\alpha$ -tocopheryl succinate," <i>Br. J. Cancer</i> , 84:87-89, 2000.
	C213	Nicolau and Sene, "Liposome-mediated DNA transfer in eukaryotic cells. Dependence of the transfer efficiency upon the type of liposomes used and the host cell cycle stage," <i>Biochim. Biophys. Acta</i> , 721:185-190, 1982.
	C214	Nicolau <i>et al.</i> , "Liposomes as carriers for in vivo gene transfer and expression," <i>Methods Enzymol.</i> , 149:157-176, 1987.
	C215	Oh <i>et al.</i> , "Conservation between animals and plants of the <i>cis</i> -acting element involved in the unfolded protein response," <i>Biochem Biophys Res Commun</i> , 301:225-230, 2003.
	C216	Pavio <i>et al.</i> , "Protein synthesis and endoplasmic reticulum stress can be modulated by the hepatitis C virus envelope protein E2 through the Eukaryotic initiation factor 2 $\alpha$ kinase PERK," <i>J. Virol</i> , 77(6):3578-3585, 2003.
✓	C217	Petryshyn <i>et al.</i> , "Detection of activated double-stranded RNA-dependent protein kinase in 3T3-F442A cells," <i>Proc. Natl. Acad. Sci., USA</i> , 85(5):1427-1431, 1988.

25746887.1

EXAMINER: /Q. Janice Li/ (06/07/2007)

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1-2	Other Art See Page 2-12	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/qjl/	C218	Petryshyn <i>et al.</i> , "Growth-related expression of a double-stranded RNA-dependent protein kinase in 3T3 cells," <i>J. Biol. Chem.</i> , 259(23):14736-14742, 1984.
	C219	Pezzella <i>et al.</i> , "Non-Small-Cell Lung Carcinoma Tumor Growth without Morphological Evidence of Neo-Angiogenesis," <i>Am. J. Pathology</i> , 151:1417-1423, 1997.
	C220	Piazza <i>et al.</i> , "Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis," <i>Cancer Res.</i> , 55(14):3110-6, 1995.
	C221	Piazza <i>et al.</i> , "Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction," <i>Cancer Res.</i> , (57):2452-59, 1997.
	C222	Piazza <i>et al.</i> , "Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels," <i>Cancer Res.</i> , (57):2909-2915, 1997.
	C223	Prasad and Edwards-Prasad, "Effects of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture," <i>Cancer Res.</i> , 42:550-554, 1982.
	C224	Prasad and Edwards-Prasad, "Vitamin E and cancer prevention: recent advances and future potentials," <i>J. Am. Coll. Nutr.</i> , 11:487-500, 1992.
	C225	Ramesh <i>et al.</i> , "Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery," <i>DNA and Cell Biol.</i> , 23:850-857, 2004.
	C226	Rao <i>et al.</i> , "Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent," <i>Cancer Res.</i> , 55(7):1464-1472, 1995.
	C227	Reddy <i>et al.</i> , "Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet," <i>Cancer Res.</i> , (50):2562-2568, 1990.
	C228	Restifo <i>et al.</i> , "Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity," <i>Curr Opin Immunol</i> , 12(5):597-603, 2000.
	C229	Ron, "Translational control in the endoplasmic reticulum stress response," <i>J. Clin Invest</i> , 110(10):1383-1388, 2002.
✓	C230	Ross <i>et al.</i> , "The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy," <i>Oncologist</i> , 8(4):307-25, 2003.

25746887.1

EXAMINER: /Q. Janice Li/ (06/07/2007)

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1-2	Other Art See Page 2-12	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C231	<del>Rudinger, "Characteristics of the amino acids as components of a peptide hormone sequence," <i>Peptide Hormones</i>, University Park Press, 1-7, June 1976.</del>
/qjl/	C232	Sakariassen <i>et al.</i> , "Angiogenesis-independent tumor growth mediated by stem-like cancer cells," <i>Proc. Natl. Acad. Sci. USA</i> , 103:16466-16471, 2006.
	C233	Sarkar <i>et al.</i> , "mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK," <i>Proc. Natl. Acad. Sci., USA</i> , 99(15):10054-10059, 2002.
	C234	Sausville <i>et al.</i> , "Clinical development of 17-allylamino, 17-demethoxygeldanamycin," <i>Curr. Cancer Drug Targets</i> , 3:377-383, 2003.
	C235	Schaefer <i>et al.</i> , "Observation of antigen-dependent CD8+ T-cell/ dendritic cell interactions in vivo," <i>Cell Immunol.</i> , 214:110-122, 2001.
	C236	Schulte and Neckers, "The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin," <i>Cancer Chemother. Pharmacol.</i> , 42(4):273-279, 1998.
	C237	Schwartz and Shklar, "The selective cytotoxic effect of carotenoids and alpha-tocopherol on human cancer cell lines in vitro," <i>J. Oral Maxillofac. Surg.</i> , 50:367-373, 1992.
	C238	Shtrichman <i>et al.</i> , "Tissue selectivity of interferon-stimulated gene expression in mice infected with dam <sup>+</sup> versus dam <sup>-</sup> <i>salmonella enterica</i> serovar typhimurium strains," <i>Infect Immun.</i> , 70:5579-5588, 2002.
	C239	Singh and Lippman, "Cancer chemoprevention. Part 2: Hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents," <i>Oncology (Williston Park)</i> , 12(12): 1787-800, 1998.
	C240	Singh and Reddy, "Molecular markers in chemoprevention of colon cancer," <i>Annals. NY Acad. Sci.</i> , (768):205-209, 1995.
↓	C241	Singh <i>et al.</i> , "Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis," <i>Carcinogenesis</i> , (15):1317-1323, 1994.
	C242	<del>Skolnick and Hettich, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>TIB Tech.</i>, 18:34-39, 2000.</del>

25746887.1

EXAMINER: /Q. Janice Li/ (06/07/2007)

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1-2	Other Art See Page 2-12	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/qjl/	C243	Steinbach <i>et al.</i> , "The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis," <i>N. Engl. J. Med.</i> , 342:1946-1952, 2000.
	C244	Su <i>et al.</i> , "Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene," <i>Cancer Res.</i> , 58, 2339-2342, 1998.
	C245	Sudhakar <i>et al.</i> , "Phosphorylation of serine 51 in initiation factor 2 $\alpha$ (eIF2 $\alpha$ ) promotes complex formation between eIF2 $\alpha$ (P) and eIF2B and causes inhibition in the guanine nucleotide exchange activity of eIF2B," <i>Biochemistry</i> , 39(42):12929-12938, 2000.
	C246	Taylor and Kingston, "E1a transactivation of human HSP70 gene promoter substitution mutants is independent of the composition of upstream and TATA elements," <i>Mol. Cell. Biol.</i> , 10:176, 1990.
	C247	Taylor and Kingston, "Factor substitution in a human HSP70 gene promoter: TATA-dependent and TATA-independent interactions," <i>Mol. Cell. Biol.</i> , 10:165, 1990.
	C248	Thompson <i>et al.</i> , "Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac," <i>J. Natl. Cancer Inst.</i> , 87(16):1259-1260, 1995.
	C249	Thun <i>et al.</i> , "Aspirin use and reduced risk of fatal colon cancer," <i>N. Engl. J. Med.</i> , 325(23):1593-1596, 1991.
	C250	Todd <i>et al.</i> , "An 80 Kb P1 clone from chromosome 3p21.3 suppresses tumor growth in vivo," <i>Oncogene</i> , 13:2387-2396, 1996.
	C251	Tomizawa <i>et al.</i> , "Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B," <i>P Nat Acad Sci USA</i> , 98:13954-13959, 2001.
	C252	Tong <i>et al.</i> , "Immune activation by Ad-mda7 (INGN 241) gene transfer in advanced patients," <i>Cancer Gene Therapy</i> , 10:S37, 2002.
	C253	Vattem <i>et al.</i> , "Inhibitory sequences in the N-terminus of the double-stranded-RNA-dependent protein kinase, PKR, are important for regulating phosphorylation of eukaryotic initiation factor 2 $\alpha$ (eIF2 $\alpha$ )," <i>Eur J Biochem</i> , 268(4):1143-1153, 2001.
✓	C254	Vermeulen <i>et al.</i> , "Lack of angiogenesis in lymph node metastases of carcinomas is growth pattern-dependent," <i>Histopathology</i> , 40:105-107, 2002.

25746887.1

EXAMINER: /Q. Janice Li/ (06/07/2007)	DATE CONSIDERED:
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/qjl/	C255	Whitesell <i>et al.</i> , "Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation," <i>Proc. Natl. Acad. Sci. USA</i> , 91(18):8324-8328, 1994.
	C256	Williams, "Signal integration via PKR," <i>Sci STKE</i> , 89:RE2, 2001. (abstract only)
	C257	Wu <i>et al.</i> , "Inhibitory effects of RRR-alpha-tocopheryl succinate on benzo(a)pyrene (B(a)P)-induced forestomach carcinogenesis in female mice," <i>World J. Gastroenterol.</i> , 7:60-65, 2001.
	C258	Yeo <i>et al.</i> , "Accumulation of unglycosylated liver secretory glycoproteins in the rough endoplasmic reticulum," <i>Biochem Biophys Res Commun</i> , 160(3):1421-1428, 1989.
	C259	You <i>et al.</i> , "Role of extracellular signal-regulated kinase pathway in RRR-alpha-tocopheryl succinate-induced differentiation of human MDA-MB-435 breast cancer cells," <i>Mol. Carcinogenesis</i> , 33(4):228-236, 2002.
	C260	You <i>et al.</i> , "RRR-alpha-tocopheryl succinate induces MDA-MB-435 and MCF-7 human breast cancer cells to undergo differentiation," <i>Cell Growth Differ.</i> , 12:471-480, 2001.
↓	C261	Yu <i>et al.</i> , "Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells," <i>Cancer Res.</i> , 61(17):6569-6576, 2001.

25746887.1

EXAMINER: /Q. Janice Li/ (06/07/2007)	DATE CONSIDERED:
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
/qjl/	A39	2006/0292157	12/28/06	Fisher <i>et al.</i>	424	155.1	12/02/05

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25737578.1

EXAMINER: /Q. Janice Li/ (06/07/2007)	DATE CONSIDERED:
---------------------------------------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

*INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)*